Navigation Links
Two Australian Teenagers Sentenced to Life for Murder

Two Australian teenagers who killed their friend and buried her under a house in Perth were setenced to life imprisonment on Wednesday . They cant be let out on prole till they are in their thirties.

The two 17-year-olds, who cannot be named because of their age, pleaded guilty in March to the wilful murder of Eliza Jane Davis last June.

Perth Children's Court President Denis Reynolds described the murder as "gruesome and merciless in the extreme".

During lengthy sentencing remarks, Judge Reynolds told the pair - who were 16 at the time of the murder - that their long history of drug use leading up to the night before the murder could not excuse what they had done.

All three girls danced together at a party on June 17, just hours before the killing.

Prosecutor Simon Stone told the court the three friends had slept in the same house after the party, Eliza in one bedroom while the killers slept in a second room.

Idly chatting the next morning, the two disturbed teenagers discovered neither of them would feel bad about killing someone, and decided to kill their friend.

After they buried the corpse, they reported her missing and pretended to help in the search before turning themselves in to police after deciding the grave was so shallow that discovery was inevitable.

The girls have since said they regret the devastating impact on Eliza's family and friends but do not feel sad she is dead.

Stone said experts considered the pair potentially dangerous to others in custody if allowed to continue their dark and enmeshed relationship.

"They planned the murder with calmness, consideration, emotional detachment and the desire to have the experience of killing someone," he said.

Judge Reynolds said that while drugs "formed an integral part of their lifestyle and psychological health", they were not the "catalyst" for the murderous behaviour of the girls o
'"/>




Page: 1 2

Related medicine news :

1. Australian Scientists Silence Cancer Gene
2. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Australian Health funds stand accused
5. Australian Court Finds Man Guilty of Spreading HIV/AIDS
6. Australian Scientists Develop Novel Drug To Combat Inflammatory Diseases
7. Sale Of Bird Flu Vaccine to US Planned: Australian Firm
8. Hepatitis C Could Infect 800,000 Australians By 2020
9. Obesity Cost More Than The Australian Health Budget
10. Australian Snake Venom Can Arrest Bleeding During Surgery And Trauma
11. Fat Virus, Ad-36 Blamed For Obesity Epidemic In Australians
Post Your Comments:
(Date:12/7/2009)... NEW ORLEANS, Dec. 7 Cell Therapeutics, ... that Ruth Pettengell, M.D. of St. George,s Hospital, ... 2009 American Society of Hematology ("ASH") Annual Meeting ... (PIX 301) clinical trial of pixantrone (the "PIX ... non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... signs of feline DNA in virus , , SUNDAY, Dec. 6 ... AIDS might be found in a tiger that lived thousands ... It appears the virus took on a bit of a ... cat remains in the virus to this day. That tiger, ... evolution of the virus that ultimately led to its infection ...
(Date:12/6/2009)... ON. Dec. 6, 2009 A new study provides ... known as venous thromboembolism (VTE). , The condition ... every year, and occurs when an abnormal clot forms ... causing pain and swelling. In some cases, the clot ... through the heart to the lungs, causing a potentially ...
(Date:12/5/2009)... significant scientific advances in the field of blood cancers, ... of how certain diseases progress in order to discover ... care. Research presented today at the 51st Annual Meeting ... therapies for managing multiple myeloma, the importance of advance ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... Against Widex and William Demant Companies, SALT LAKE ... ), a leading producer of advanced digital hearing aids,issues ... of press,releases related to a jury award of $31 ... Inc. v. Sonic Innovations,Inc., et al. While this action ...
... The first genome-wide search for genes governing social behavior ... the amoebae Dictyostelium discoideum -- have more than 100 ... study by scientists at Rice University and Baylor College ... the journal Nature. It marks one of the first ...
... Senior Living Inc.,(NYSE: BKD ) announced today that ... 2007 financial results after the market closes on Wednesday,February ... to discuss,the results on February 28, 2008 at 10:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069,(from ...
... at The Wistar Institute have collaborated on a major advance ... the deadliest cancers in humans. The culmination of 10 years ... new cancer therapies. , During much of its lifetime, ... in an inactive form, stored inside densely knotted structures in ...
... to close FMLA loopholes, ALEXANDRIA, Va., Feb. ... devoted to human resource management,appeared before a Senate ... the,Family Medical and Leave Act (FMLA) be closed., ... have two primary concerns with the act,s,regulations--the definitions ...
... first quarter operating results further convinces ... a discount, NEW YORK, Feb. 13 Accipiter ... 10% of the outstanding,shares of common stock of VistaCare, ... delivered a letter to VistaCare,s Board of Directors stating,that ...
Other Medicine News:Health News:Sonic Innovations Not Included in Adverse Jury Verdict 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 3Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 3Health News:Is a Common Cold a 'Serious Health Condition'? 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 3Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 4
(Date:12/4/2009)... 4 A new, $2.8 million, four-year federal grant ... of Medicine and their collaborators at Wake Forest University ... blood degrades over time and how to address the ... been associated with increased risk for cardiovascular events and ...
(Date:12/4/2009)... Deliveries are Transported ,, PHILADELPHIA, Dec. 4 ... the American Red Cross are hard at work educating ... endure that could potentially put Philadelphia,s blood supply at ... and set up a picket line yesterday when their ...
(Date:12/4/2009)... Imaging, LLC, an independent provider of CT, MRI ... and healthcare providers, is excited to announce it ... Health Care, a nationally-recognized, prestigious gold seal of ... Shared Imaging accreditation is system-wide for its mobile ...
Breaking Medicine Technology:NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 57584 1The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 57584 2Ohio Healthcare Organization Responds to Healthcare Reform 57581 1Ohio Healthcare Organization Responds to Healthcare Reform 57581 2Ohio Healthcare Organization Responds to Healthcare Reform 57581 3Ohio Healthcare Organization Responds to Healthcare Reform 57581 4Ohio Healthcare Organization Responds to Healthcare Reform 57581 5FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution 57579 1FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution 57579 2
... TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar ... ... Population, SAN FRANCISCO, June ... dyslipidemia and type 2 diabetes,that were enrolled in a Phase III ...
... Annual Scientific Sessions, SAN FRANCISCO, June 7 ... dose-finding study for its new,injectable diabetes compound AVE0010, ... Association,s (ADA) 68th Annual Scientific Sessions,meeting in San ... was well tolerated and significantly,improved glycemic control versus ...
Other Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: